Ageing slows neuronal protein degradation in mice, leading to widespread accumulation and aggregation of long-lived proteins, particularly at synapses. As neuronal clearance declines, microglia ...

Northwestern Medicine scientists have zeroed in on a cellular gatekeeper that may hold promise for treating abnormal protein ...

Dewpoint has selected a novel small molecule to prevent the formation of abnormal TDP-43 protein clumps in ALS and other ...

Researchers at Wakayama Medical University in Japan have discovered that amyloid-β deposits disrupt the formation of the placenta and may therefore contribute to the development of preeclampsia during ...

Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis are marked by the buildup of ...

Proteins form the building blocks of life, but when they form unusual clumps inside the brain, they raise an alarm that something isn't right.

The involvement of glial cells in Alzheimer's disease (AD) has been mostly viewed as a secondary adaptive response to ...

Protein aggregates, damaged organelles, and invading bacteria are identified and removed in healthy cells. An international ...

Prefoldin 5 stabilises neuronal microtubules and suppresses Tau-mediated neurotoxicity, offering a potential therapeutic target for tauopathies.

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

Explore why tau still lacks treatments despite its critical role in Alzheimer's disease and other tauopathies.